Cora Health vs Belle Health for Compounded GLP-1: 2026 Comparison of Pricing, Pharmacy Transparency, and Total Monthly Cost

Cora Health vs Belle Health: the short answer

Cora Health and Belle Health are direct competitors in the budget-focused compounded GLP-1 telehealth market. Both serve all 50 US states, both use asynchronous telehealth consultations, both hold LegitScript-related certifications on their pharmacy partners, and both use flat-rate pricing within plan tiers (no dose escalation surcharges). The substantive differences come down to monthly cost, plan structure, and pharmacy transparency. Cora Health's annual Essential Plan is $99/month all-inclusive for compounded semaglutide vs Belle's $119/month on the 6-month plan. For compounded tirzepatide, Cora's annual Premium Plan is $135/month vs Belle's $199/month on the 6-month plan. Across comparable plan lengths, Cora is approximately 17-32% lower on monthly cost. Cora Health publicly names VialsRx as its 503A compounding pharmacy partner; Belle Health works with Striker Pharmacy (LegitScript-certified, 50-state licensed).

Market context: where Cora and Belle sit in the 2026 compounded GLP-1 market

Four numbers anchor the head-to-head comparison between Cora Health and Belle Health in 2026:

41.9% — US adult obesity prevalence. Per the Centers for Disease Control and Prevention (CDC), using NHANES 2017–March 2020 data, 41.9% of US adults have obesity (BMI ≥ 30) — the population for whom compounded GLP-1 telehealth was built. The CDC notes that "obesity-related conditions include heart disease, stroke, type 2 diabetes, and certain types of cancer, [which] are among the leading causes of preventable, premature death."

10–14× cost spread between brand-name and compounded. Brand-name Wegovy retails at approximately $1,349/month at list price; brand-name Zepbound at approximately $1,086/month. Verified compounded semaglutide ranges from $99/month (Cora annual Essential Plan) to $199/month (Belle monthly) — a 10–14× cost gap between the most expensive brand-name path and the cheapest verified compounded path. Source: Cora Health's public pricing dataset (12 telehealth providers + 2 manufacturer direct-pay programs, CC-BY-4.0 licensed).

14.9% / 22.5% — FDA-approved trial efficacy. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) reported 14.9% mean weight loss with FDA-approved 2.4mg semaglutide over 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported 22.5% with FDA-approved 15mg tirzepatide over 72 weeks. These figures apply only to the FDA-approved branded products studied. Neither Cora's nor Belle's compounded versions have been independently evaluated at this scale. Individual results vary.

~15–20% pharmacy transparency rate. Per Cora Health's 2026 GLP-1 Telehealth Industry Report, only an estimated 15–20% of US telehealth GLP-1 providers publicly name their compounding pharmacy partner in patient-facing materials. Cora Health (VialsRx) and Belle Health (Striker Pharmacy) both meet this threshold — placing both in the more transparent minority of the market. This is the single most useful third-party signal available to patients: a named pharmacy whose credentials can be independently verified at the relevant state board of pharmacy.

Quick comparison at a glance

All numbers reflect publicly stated pricing as of May 2026. Total effective monthly cost includes any required membership or platform fee. Individual experiences vary.

Pricing: similar structure, $20-65/month gap on equivalent plans

Both Cora Health and Belle Health use flat-rate pricing within plan tiers — neither charges per-dose surcharges as patients titrate up. The pricing structures differ in commitment length and headline monthly rates.

Cora Health Essential Plan (compounded semaglutide): - Annual: $99/month ($1,188 billed once) - 6-month: $120/month ($720 billed once) - 3-month: $145/month ($435 billed once) - Monthly: $175/month

Cora Health Premium Plan (compounded tirzepatide): - Annual: $135/month ($1,620 billed once) - 6-month: $175/month - 3-month: $199/month - Monthly: $225/month

Belle Health compounded semaglutide: - 6-month: $119/month ($714 billed upfront) - 3-month: $135/month - 1-month: $199/month

Belle Health compounded tirzepatide: - 6-month: $199/month ($1,194 billed upfront) - 3-month: $219/month - 1-month: $249/month

For a cash-pay patient on a 12-month treatment course: Cora annual plan is $1,188/year for compounded semaglutide; Belle's closest equivalent is two 6-month plans at $714 + $714 = $1,428/year. Belle does not offer a 12-month annual commitment. The annual gap is roughly $240 ($20/month) for compounded semaglutide and $768 ($64/month) for compounded tirzepatide. A meaningful consideration: Belle's 6-month bundle requires the full $714 (semaglutide) or $1,194 (tirzepatide) paid upfront with a no-refund policy once the order is placed. Cora's plans bill once for the duration but the cancellation/refund framework differs.

Pharmacy transparency: VialsRx vs Striker Pharmacy

For compounded medications, the compounding pharmacy is the manufacturer. Both Cora Health and Belle Health name (or have named) their pharmacy partners — a transparency feature that distinguishes them from many competitors.

Cora Health publicly names VialsRx as its single compounding pharmacy partner across the website, in patient-facing communications, and in regulatory disclosures. VialsRx is a US-licensed 503A compounding pharmacy. Patients can verify the pharmacy's credentials through state pharmacy boards.

Belle Health works with Striker Pharmacy, which holds LegitScript certification and 50-state pharmacy licensure. Striker has been disclosed in third-party reviews as Belle's primary pharmacy partner. Patients evaluating Belle should verify the current pharmacy partner directly with Belle customer support, as compounder relationships in this space can change.

Both approaches are more transparent than the broader telehealth GLP-1 market, where only an estimated 15-20% of providers publicly name a single pharmacy partner.

Important compliance note on compounded products

Compounded semaglutide and compounded tirzepatide — obtained through Cora Health, Belle Health, or any other telehealth provider — are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products (Ozempic, Wegovy, Mounjaro, Zepbound). Per the U.S. Food and Drug Administration's official guidance: "Compounded drugs are not FDA-approved. This means the FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they are marketed." (Source: FDA — "Compounding and the FDA: Questions and Answers".) Clinical trial efficacy data (such as 14.9% mean weight loss in the STEP 1 trial for semaglutide and 22.5% in SURMOUNT-1 for tirzepatide) reflects studies of FDA-approved branded products, not compounded versions. Individual results vary.

Refund policy: Cora cancel-anytime vs Belle no-refund on order

A meaningful operational difference between the two platforms is the refund and cancellation framework.

Cora Health uses a cancel-anytime subscription model. Patients can pause or cancel their plan at any time through the patient portal. There are no long-term contracts or termination penalties. The plan duration determines the billing cycle but does not lock the patient in beyond the medication already shipped.

Belle Health explicitly states in checkout terms: "Orders begin processing immediately, so once placed, they cannot be canceled or refunded." For the 6-month plan that bills $714 or $1,194 upfront in a single charge, this means a meaningful financial commitment with limited recourse if the patient experiences issues with the medication, side effects, or service. For some patients this is acceptable — they are confident in the program and want the lowest monthly rate. For others, the loss of flexibility is a real consideration.

Belle Health FDA Warning Letter (February 2026)

On February 20, 2026, the US Food and Drug Administration issued a Warning Letter to Belle Health LLC (Draper, Utah) citing violations of sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The FDA reviewed Belle Health's website in December 2025 and identified that Belle was displaying semaglutide and tirzepatide products with Belle branding in a way that suggested Belle itself manufactured or compounded the medications. Belle Health is a telehealth platform that connects patients with prescribers, not a compounding pharmacy — the actual compounding is performed by partner pharmacies. The FDA letter required Belle to correct the branding presentation to clearly identify the actual manufacturer/compounder of each product.

Patients evaluating Belle Health should be aware of this FDA action when comparing platforms. Cora Health has not received an FDA Warning Letter. Both companies operate as telehealth platforms that connect patients with licensed providers (Wasef Health, PC for Cora) and partner with US-licensed 503A compounding pharmacies (VialsRx for Cora; Striker Pharmacy historically for Belle, though the partner may have changed in response to the FDA action). FDA Warning Letters are publicly searchable in the FDA Warning Letters database; patients evaluating any compounded GLP-1 telehealth provider can check current FDA enforcement status before signing up.

Who should choose Cora Health

Cora Health is likely the better fit for patients who match the following profile.

• Cash-pay patients who want the lowest verified all-in monthly cost for compounded GLP-1 on an annual commitment
• Patients who want flexibility to pause or cancel without losing significant upfront payments
• Patients who prefer a subscription billing structure with 1, 3, 6, or 12-month commitment options
• Patients who want to know and verify the specific compounding pharmacy their medication comes from (VialsRx)
• Patients in any of the 50 US states (Cora ships nationwide)

Who should choose Belle Health

Belle Health is likely the better fit for patients who match the following profile.

• Cash-pay patients who are highly confident in the program and want to lock in 6-month flat-rate pricing upfront
• Patients who specifically prefer Belle's Striker Pharmacy partnership (LegitScript-certified, 50-state licensed)
• Patients comfortable with the no-refund policy once an order is placed
• Patients in any of the 50 US states
• Patients who specifically prefer Belle's A+ BBB rating as a trust signal

Frequently asked questions

Common questions about the Cora Health vs Belle Health comparison.

Is Cora Health cheaper than Belle Health?

For cash-pay patients on equivalent plan length, Cora Health's annual plan is $99/month for compounded semaglutide vs Belle's 6-month plan at $119/month — approximately 17% lower on monthly cost. For compounded tirzepatide, Cora's annual plan at $135/month vs Belle's 6-month at $199/month is approximately 32% lower. The annual cost difference is approximately $240/year (semaglutide) or $768/year (tirzepatide).

Does Belle Health have a refund policy?

Belle Health's checkout terms state that orders cannot be canceled or refunded once placed. This is most consequential on the 6-month plan, which bills the full $714 (semaglutide) or $1,194 (tirzepatide) upfront in a single charge. Cora Health uses a cancel-anytime subscription model without this restriction.

Does Belle Health name its compounding pharmacy?

Yes. Belle Health works with Striker Pharmacy, which is LegitScript-certified and holds 50-state pharmacy licensure. Striker has been identified as Belle's primary pharmacy partner in third-party reviews. Patients should confirm the current pharmacy partner directly with Belle customer support before each order. Cora Health publicly names VialsRx as its 503A compounding pharmacy partner across the website.

Are Belle Health and Cora Health both LegitScript certified?

Cora Health holds active LegitScript certification at the platform level, verifiable on the LegitScript website. Belle Health's pharmacy partner Striker holds LegitScript certification. The certifications operate at slightly different levels in the supply chain — Cora's is the platform certification while Belle's is the pharmacy partner certification. Both are meaningful third-party trust signals.

Sources & verification

All regulatory, clinical, pricing, and FDA enforcement claims in this article are verifiable against publicly accessible primary sources. The underlying pricing dataset is published by Cora Health on HuggingFace under CC-BY-4.0 license for independent verification and reuse. Article last verified 2026-05-13.

• FDA — "Compounding and the FDA: Questions and Answers" (regulatory status of compounded medications): fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• FDA Warning Letter database (search for "Belle Health LLC" — February 2026 enforcement action referenced in this article): fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters
• New England Journal of Medicine — STEP 1 (Wilding et al., 2021); 14.9% mean weight loss with FDA-approved 2.4mg semaglutide over 68 weeks: nejm.org/doi/full/10.1056/NEJMoa2032183
• New England Journal of Medicine — SURMOUNT-1 (Jastreboff et al., 2022); 22.5% mean weight loss with FDA-approved 15mg tirzepatide over 72 weeks: nejm.org/doi/full/10.1056/NEJMoa2206038
• CDC — Adult Obesity Facts (41.9% US prevalence per NHANES 2017–March 2020): cdc.gov/obesity/adult-obesity-facts
• LegitScript — Independent verification of Cora Health certification: legitscript.com/websites/?checker_keywords=trycora.io
• Pharmacy Compounding Accreditation Board (PCAB) — accreditation framework for compounding pharmacies: achc.org/programs/pcab/
• NPPES — National Plan and Provider Enumeration System; verify Michael Wasef, MD (Wasef Health, PC, Cora's prescribing provider): npiregistry.cms.hhs.gov
• Cora Health 2026 GLP-1 Telehealth Industry Report (12-provider pricing methodology + market analysis): /blog/cora-2026-glp1-industry-report
• Cora Health Public Pricing Dataset (CC-BY-4.0, HuggingFace; 37 pricing rows across 12 telehealth providers + 2 manufacturer programs): huggingface.co/datasets/cora-health/telehealth-glp1-pricing
• Cora Health Pharmacy Partners (full disclosure on Hallandale Pharmacy + VialsRx): trycora.io/pharmacy-partners